Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode hundreds of pages of oncology jargon in Processa Pharmaceuticals’ filings? Each Form 10-K outlines how the company funds its Next Generation Chemotherapy (NGC) pipeline, while every 8-K details new clinical milestones or FDA feedback that can move PCSA’s share price overnight. Missing one paragraph could mean overlooking a cash-raising shelf registration or a trial setback.
StockTitan’s AI reads the documents for you. Our platform delivers plain-English summaries of the Processa Pharmaceuticals annual report 10-K simplified, highlights R&D spending trends in the latest Processa Pharmaceuticals quarterly earnings report 10-Q filing, and flags dilution risks buried in S-3 prospectuses. Need real-time alerts? We stream Processa Pharmaceuticals Form 4 insider transactions as soon as they hit EDGAR, so you can track executive confidence without wading through pdfs.
Use our guided view to jump straight to the sections investors ask about most:
- Cash runway projections and trial budgets in 10-Q MD&A
- NGC clinical results and FDA responses in 8-K material events explained
- Processa Pharmaceuticals insider trading Form 4 transactions with AI-generated context on each buy or sell
- Board pay packages inside the Processa Pharmaceuticals proxy statement executive compensation
Whether you’re asking “How do I read Processa’s 10-K?” or searching for “understanding Processa Pharmaceuticals SEC documents with AI,” StockTitan delivers every filing type—10-K, 10-Q, 8-K, S-3, SC 13G, and more—complete with expert notes and real-time updates. Spend minutes, not hours, turning dense biotech disclosures into actionable insight.
David Young, President of Research & Development and a director at Processa Pharmaceuticals, Inc. (PCSA), reported equity awards granted on 10/01/2025. The filing shows 111,000 Restricted Stock Units granted, each converting to one share upon vesting: one-third vests on 10/01/2026 and the remainder vests monthly over two years until 10/01/2028. It also reports 333,000 stock options with an exercise price of $0.198; those options vest one-third on the first anniversary of the grant and the remainder ratably over the next two years. Following the transactions the reporting person beneficially owns the awarded 111,000 RSUs and 333,000 options. The Form is signed by an attorney-in-fact on 10/03/2025.
Processa Pharmaceuticals (PCSA) reported insider grants to CEO and director George Ng dated 10/01/2025. He was awarded 256,000 restricted stock units (RSUs) that vest one‑third on 10/01/2026 and then monthly over two years until fully vested on 10/01/2028. He also received 768,000 stock options with an exercise price of $0.198, vesting one‑third on the first anniversary and the remainder ratably over the next two years. Both awards are reported as directly owned following the grants. The Form 4 was signed on behalf of Mr. Ng by an attorney‑in‑fact and shows no dispositions or other securities changes.
Wendy Guy, identified as the reporting person and listed as Chief Administrative Officer, submitted an amended Form 4 for Processa Pharmaceuticals, Inc. (PCSA). The filing states a transaction date of 07/24/2025 and records a disposition of 26,339 shares of the issuer's common stock (transaction code V). After the reported transaction the filing shows beneficial ownership of 8,335 shares held indirectly through CorLyst, LLC.
The amendment expressly notes it was filed to retract a prior Form 4 that was filed in error. The amended Form 4 is signed via power of attorney on behalf of Wendy Guy by John J. Wolfel and dated 09/18/2025.
Processa Pharmaceuticals (PCSA) insider amendment: This amended Form 4, filed by Director Justin W. Yorke, corrects a prior filing submitted in error and reports changes in his holdings. The filing shows a disposition of 3,737 shares of common stock on 07/24/2025. After the reported transactions, Yorke beneficially owns 12,400 shares indirectly via a Directed Trust Company account for his IRA and 31,232 shares indirectly via Richland Fund, LLC. The amendment also reports warrants exercisable for common stock at a $0.65 price (expiring 01/29/2030) associated with the Directed Trust Company IRA: 12,400 and 6,200 underlying shares respectively. The form is signed by attorney-in-fact John J. Wolfel on behalf of Yorke.
Processa Pharmaceuticals, Inc. (PCSA) filed an amended Form 4 to correct an earlier filing. The amendment states the prior Form 4 was filed in error and retracts that prior report. The filing lists David Young (President, Research & Development and director) as the reporting person and shows a transaction date of 07/24/2025. The Table I entries indicate a disposition of 217,332 common shares and beneficial ownership reported as 30,985 shares direct plus indirect holdings: 10,786 shares via the Young-Plaisance Revocable Trust, 18,544 shares via CorLyst, LLC. The amendment is signed by David Young via attorney-in-fact John J. Wolfel on 09/18/2025.
Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, Inc. (PCSA), amended a prior filing to report ownership of 28,000 restricted stock units. The RSUs convert to common stock and are structured to vest 50% on July 16, 2025, with the remaining 50% contingent on achievement of specified performance criteria. The amendment retracts an earlier Form 4 that was filed in error. The reported transaction date is July 24, 2025, and the amended Form 4 was signed by attorney-in-fact on September 18, 2025.
Geraldine Pannu, a director of Processa Pharmaceuticals, Inc. (PCSA), filed an amended Form 4 to correct prior reporting of her restricted stock and resulting direct beneficial ownership. The amendment discloses an acquisition code A for 31,206 shares of restricted stock acquired with a $0 price and underlying 31,206 shares of common stock. After the correction, Ms. Pannu directly beneficially owns 36,275 shares of common stock. The restricted shares are subject to vesting and will vest on the earlier of June 28, 2025 or the next annual meeting of stockholders, subject to certain distribution requirements. The filing states the amendment retracts a prior Form 4 that was filed in error and corrects the beneficially owned shares previously reported.
Processa Pharmaceuticals (PCSA) reporting person George K. Ng amended a prior Form 4 to correct an earlier filing error. The amendment shows Mr. Ng is both a director and the Chief Executive Officer. The filing discloses indirect beneficial ownership of 87,200 shares of common stock held through warrants and 20,000 shares held by the Ng Cha Family Trust, as well as separate warrant holdings converting into 87,200 and 43,600 common shares at a $0.65 exercise price expiring 01/29/2030. The earliest transaction date listed is 07/24/2025, and the amendment notes the prior Form 4 was filed in error.
Processa Pharmaceuticals, Inc. (PCSA) amended a prior Form 4 to correct reported insider holdings for reporting person Neal James R, who is identified as a director. The filing shows restricted stock granted with $0 price that vested subject to the earlier of June 28, 2025 or the next annual meeting, and records an acquisition of 31,206 restricted shares. The filing reports 36,275 common shares beneficially owned following the reported transactions. The amendment states it was filed to retract a prior Form 4 that was filed in error and to correct the beneficially owned shares previously reported on a Form 4 filed September 18, 2024. The form was signed by an attorney-in-fact on behalf of the reporting person.
FAQ
What is the current stock price of Processa Pharmaceuticals (PCSA)?
What is the market cap of Processa Pharmaceuticals (PCSA)?
